Patients with proliferative diabetic retinopathy may bleed into the vitreous from

retinal neovascularization. These patients must be managed aggressively with eye-

saving panretinal photocoagulation, often combined with anti-VEGF (vascular
endothelial growth factor) therapy with intravitreal injections of ranibizumab
(Lucentis), aflibercept (Eylea), or bevacizumab (Avastin), although such anti-
VEGF therapy is not approved by the US Food and Drug Administration. If the
blood prevents visualization of the retina, ultrasound examination must be
performed to rule out traction retinal detachment.